TNF-alpha drugs for Rheumatoid Arthritis

19 tracked TNF-alpha drugs in the Rheumatoid Arthritis race. The class explanation lives on the TNF-alpha page; the full indication pipeline across every mechanism is on the Rheumatoid Arthritis page.

19 approved / phase 4

Head-to-head evidence: adalimumab vs adalimumab-aacf (Idacio) · adalimumab vs adalimumab-aaty (Yuflyma) · adalimumab vs adalimumab-adaz (Hyrimoz) · adalimumab vs adalimumab-adbm (Cyltezo) · adalimumab vs adalimumab-afzb (Abrilada) · adalimumab vs adalimumab-aqvh (Yusimry)

The roster

← all TNF-alpha drugs